免疫介导心脏疾病新策略PPT.ppt

New Strategies for Immune-mediated Heart Diseases;Immune-mediated heart diseases;Immune-mediated heart diseases;Inflammation in coronary arteriosclerosis and atherogenesis PPARγ (Peroxisome proliferator-activated receptor-γ) 　　 　　NFκB ;Acute cardiac allograft rejection;Chronic cardiac rejectionGraft arterial disease (GAD); Chronic cardiac allograft rejection Cardiac allograft vasculopathy;8 Weeks after Transplantation;;Suppression of SMC Proliferation after Interaction with Splenocytes by Pioglitazone or Telmisartan;Summary 1;Inflammation in coronary arteriosclerosis and atherogenesis PPARγ (Peroxisome proliferator-activated receptor-γ) 　　 　　 NFκB ;LPS;Stimuli 　Anoxia 　Reactive oxygen species 　LPS 　Cytokines (IL-1β, TNFα) 　Re-oxygenation 　Lipoprotein 　Thrombin;;;Acute MyocarditisExperimental Allergic Myocarditis in Rats;NFkB decoy reduces extent of autoimmune myocariditis;Method of gene transfer to cardiac allograft;VCAM-1;;Inhibition of intimal hyperplasia by NF-kB decoy transfection;Japan Trial to Prevent Restenosis After Stent using　NFkB decoy Oligodeoxynucleotides as Gene Therapy ( J-PRAN );Channel Balloon (Remedy);NF-kB decoy: case 1 (49-y-o male);　;Patients with Restenosis ( 75% by QCA);Conclusions;;;IL-10;Suppression of T cell Proliferation by Telmisartan in Mixed Lymphocyte Reaction;Ultrasound + microbubbles increase efficacy of transfection;Suppression of Neointimal Formation by NF-κB Decoy;Vascular remodeling after injury